UVA Tracking #
Stephen H Caldwell
ContactCheree Denby Taylor
Official Trial Title
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F
The Gastroenterology & Hepatology seeks adults over age 18 with NASH for a research study. The purpose of the study is see if an investigational drug (lanifibranor) is effective at reducing fibrosis.
Study involves taking an experimental medicine/placebo by mouth daily, blood draws, liver biopsy, fibroscan, EKGs, optional DEXA scans, and daily weight measurements. Study involves at least 22 visits to UVA over approximately 7 years.
Study-related exams, tests and experimental medication provided free of charge.